First photochromic lens approved in Europe

Article

Medennium has obtained CE mark clearance to market its photochromic intraocular lens (IOL), Aurium in Europe, making it the first lens of its kind to be introduced to the cataract lens market.

Medennium has obtained CE mark clearance to market its photochromic intraocular lens (IOL), Aurium in Europe, making it the first lens of its kind to be introduced to the cataract lens market.

As part of the approval process, clinical data from two sites were examined. Fifteen patients received the lens in one eye and a controlled IOL with yellow colour in the fellow eye. At six-months follow-up the Arium lenses offered better best corrected visual acuity (BCVA) than the control lens, especially under weak light conditions.

Medennium will initially launch the lens in selected European countries and it hopes that by September of this year it should be available to all European cataract surgeons.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.